Fiji: an open-source platform for biological-image analysis
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients Tirzepatide had been in shortage since 2022 The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list, which some industry officials and medical experts argue will complicate access for some patients
The platform reports high success rates, with Nourish patients experiencing 8% weight loss, a 1.3-point A1C reduction, a 31-point LDL cholesterol reduction and a 23-point systolic blood pressure reduction, which it says result in over $2,000 per patient in annual cost savings for health plans
The ADA and CDS guidelines have recommended it as the first-line hypoglycemic agent for T2DM with a high risk of ASCD, chronic kidney disease, and obesity
OneFlorida+ consists of 14 health care organizations and contains records for 21 million adults treated in Florida, Georgia and Alabama
What Is the Recommended Glutathione IV Treatment Schedule
